BioReliance (Merck) vs ReciBioPharm: CDMO Comparison
How does BioReliance (Merck) compare to ReciBioPharm?
As of Jun 2026, BioReliance (Merck): 6 FDA inspections (including 2 NAI, 4 VAI and 0 OAI), 10 EMA/MHRA GMP certificates. Signal Score 80.3. ReciBioPharm: no FDA inspections on file, 3 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of BioReliance (Merck) and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- BioReliance (Merck) has more FDA inspections on record (6 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- BioReliance (Merck) has stronger MHRA / UK coverage (10 compliant certificates vs 3).
Across the cross-modality scorecard, ReciBioPharm carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: BioReliance (Merck) vs ReciBioPharm
How does BioReliance (Merck) compare to ReciBioPharm?
On CDMO Signal's composite Signal Score, BioReliance (Merck) is 80/100 and ReciBioPharm is 83/100; BioReliance (Merck) has 6 FDA inspections on record vs 0 for ReciBioPharm; European coverage is 10 active EMA+MHRA certificates for BioReliance (Merck) vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, BioReliance (Merck) or ReciBioPharm?
Both BioReliance (Merck) and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioReliance (Merck) has 6 FDA inspections on record; ReciBioPharm has 0.
How do BioReliance (Merck) and ReciBioPharm compare on European GMP coverage?
BioReliance (Merck) holds 0 active EMA GMP certificates and 10 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
BioReliance (Merck) carries a Signal Score of 80/100 and ReciBioPharm carries 83/100 — essentially tied for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →